share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外国发行人报告
美股sec公告 ·  05/20 09:05
Moomoo AI 已提取核心信息
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, announced that its Vice President of R&D, Dr. Shiran Zimri, will participate in the 3rd Annual ALS Drug Development Summit on May 22, 2024. Dr. Zimri is set to present the latest findings from the phase 2b clinical trial of PrimeC, the company's lead drug candidate for ALS treatment. The presentation will focus on the potential of combination therapy in ALS and showcase the progress of PrimeC, which has shown a statistically significant 43% slowing of disease progression in high-risk ALS patients compared to placebo. The company also highlighted the positive reception of the PARADIGM trial outcomes and plans to advance PrimeC to the next stage of development. The trial's results indicated that PrimeC could slow disease progression beyond the level afforded by the current FDA-approved ALS drug, Riluzole. NeuroSense is dedicated to developing treatments for neurodegenerative diseases and believes that combination therapies targeting multiple pathways are key to addressing these complex conditions.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, announced that its Vice President of R&D, Dr. Shiran Zimri, will participate in the 3rd Annual ALS Drug Development Summit on May 22, 2024. Dr. Zimri is set to present the latest findings from the phase 2b clinical trial of PrimeC, the company's lead drug candidate for ALS treatment. The presentation will focus on the potential of combination therapy in ALS and showcase the progress of PrimeC, which has shown a statistically significant 43% slowing of disease progression in high-risk ALS patients compared to placebo. The company also highlighted the positive reception of the PARADIGM trial outcomes and plans to advance PrimeC to the next stage of development. The trial's results indicated that PrimeC could slow disease progression beyond the level afforded by the current FDA-approved ALS drug, Riluzole. NeuroSense is dedicated to developing treatments for neurodegenerative diseases and believes that combination therapies targeting multiple pathways are key to addressing these complex conditions.
临床阶段的生物技术公司NeuroSense Therapeutics Ltd. 宣布，其研发副总裁希兰·齐姆里博士将于2024年5月22日参加第三届年度ALS药物开发峰会。Zimri博士将介绍PrimeC的2b期临床试验的最新发现，PrimeC是该公司ALS治疗的主要候选药物。该演讲将重点介绍肌萎缩性侧索硬化症联合疗法的潜力，并展示PrimeC的进展。与安慰剂相比，高危肌萎缩性侧索硬化症患者的疾病进展减缓了43％，具有统计学意义。该公司还强调了PARADIGM试验结果的积极接受以及将PrimeC推进到下一阶段开发的计划。该试验的结果表明，PrimeC可以将疾病进展减缓到目前经美国食品药品管理局批准的肌萎缩性侧索硬化症药物利鲁唑所能承受的水平以上。NeuroSense致力于开发神经退行性疾病的治疗方法，并认为针对多种途径的联合疗法是解决这些复杂疾病的关键。
临床阶段的生物技术公司NeuroSense Therapeutics Ltd. 宣布，其研发副总裁希兰·齐姆里博士将于2024年5月22日参加第三届年度ALS药物开发峰会。Zimri博士将介绍PrimeC的2b期临床试验的最新发现，PrimeC是该公司ALS治疗的主要候选药物。该演讲将重点介绍肌萎缩性侧索硬化症联合疗法的潜力，并展示PrimeC的进展。与安慰剂相比，高危肌萎缩性侧索硬化症患者的疾病进展减缓了43％，具有统计学意义。该公司还强调了PARADIGM试验结果的积极接受以及将PrimeC推进到下一阶段开发的计划。该试验的结果表明，PrimeC可以将疾病进展减缓到目前经美国食品药品管理局批准的肌萎缩性侧索硬化症药物利鲁唑所能承受的水平以上。NeuroSense致力于开发神经退行性疾病的治疗方法，并认为针对多种途径的联合疗法是解决这些复杂疾病的关键。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息